1ST IN ITS CLASS.‡
1ST IN MARKET.
IN THE 1ST YEAR.
Most prescribed in its class‡ by Neurologists, PCPs, NPs, and PAs1
• Over 33,000 HCPs have prescribed UBRELVY more than 400,000 times1,5
• More than 160,000 patients treated with UBRELVY1
• 90% of commercial lives covered1
– As of 9/20. Prior Authorization and other restrictions may apply.
†Based on retail and non-retail monthly prescription data from IQVIA on a 6-month rolling basis as of 01/21. ‡gepants for the acute treatment of migraine.
UBRELVY EFFICACY STORY
STUDY DESIGN
SEE THE STUDY DESIGNUBRELVY QUICKLY RELIEVES MIGRAINE PAIN WITH JUST ONE DOSE1,2
61.7% (UBRELVY 50 mg) vs 48.7% (placebo) at 2 hours
EXPAND TO SEE FULL RESULTSELIMINATION OF MIGRAINE
HEADACHE PAIN WITH ONE DOSE1,3,4
20.5% (UBRELVY 50 mg) vs 13% (placebo) at 2 hours
EXPAND TO SEE FULL RESULTSUBRELVY— FUNCTIONAL IMPROVEMENT DATA WITH JUST ONE DOSE1
64% (UBRELVY 100 mg) vs 54% (placebo) at 2 hours
EXPAND TO SEE FULL RESULTSEVERY MIGRAINE PATIENT
IS DIFFERENT
Consider UBRELVY for a range of patient types.
UBRELVY IS AVAILABLE IN BOTH 50 MG AND 100 MG TABLETS1




RESOURCE CENTER
Select a resource below to learn more about UBRELVY.
english
PATIENT BROCHURE (ENGLISH)spanish
DOSING FORMchinese
MEDICAL INFORMATION REQUESTProgram
PATIENTSAVINGS PROGRAM